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A B S T R A C T
Purpose
To determine the safety of sentinel lymph node biopsy as a replacement for inguinal femoral
lymphadenectomy in selected women with vulvar cancer.
Patients and Methods
Eligible women had squamous cell carcinoma, at least 1-mm invasion, and tumor size  2 cm
and  6 cm. The primary tumor was limited to the vulva, and there were no groin lymph nodes that
were clinically suggestive of cancer. All women underwent intraoperative lymphatic mapping,
sentinel lymph node biopsy, and inguinal femoral lymphadenectomy. Histologic ultra staging of the
sentinel lymph node was prescribed.
Results
In all, 452 women underwent the planned procedures, and 418 had at least one sentinel lymph
node identified. There were 132 node-positive women, including 11 (8.3%) with false-negative
nodes. Twenty-three percent of the true-positive patients were detected by immunohistochemical
analysis of the sentinel lymph node. The sensitivity was 91.7% (90% lower confidence bound,
86.7%) and the false-negative predictive value (1-negative predictive value) was 3.7% (90% upper
confidence bound, 6.1%). In women with tumor less than 4 cm, the false-negative predictive value
was 2.0% (90% upper confidence bound, 4.5%).
Conclusion
Sentinel lymph node biopsy is a reasonable alternative to inguinal femoral lymphadenectomy in
selected women with squamous cell carcinoma of the vulva.
J Clin Oncol 30:3786-3791. © 2012 by American Society of Clinical Oncology
INTRODUCTION
The modern sentinel lymph node biopsy (SLNB)
concept was proposed by Morton et al1 as an
alternative to observation or elective regional
lymphadenectomy in women with early cutaneous
melanoma. It hypothesizes that early lymphatic
drainage from a primary tumor progresses to a pre-
ferred nodal drainage basin in a nonrandom fash-
ion. The principle lymph node, or sentinel lymph
node (SLN), is identified by the combination of pre-
operative lymphoscintigraphy and intraoperative
localization by using blue dye and radiocolloid. This
technique provides the opportunity for early inter-
vention in women with SLN metastases and spares
SLN-negative women the morbidity of unnecessary
regional lymphadenectomy. Clinical trials have es-
tablished the procedure as an integral component in
the management of women with melanoma and
breast cancer.2,3
Vulvar cancer is a relatively uncommon cancer
affecting fewer than 4,000 women in the United
States each year.4 Standard treatment consists of
wide radical excision of the primary tumor and in-
guinal femoral lymphadenectomy. Even with the
use of contemporary surgical techniques, half the
womenwhoundergotreatmentofvulvarcancersuffer
a wound complication.5 While wound disruption and
acute infections are common and predominately
short-lived complications, lymphedema and cellulitis
canbelifelongissues.Unfortunately, inthelastcentury,
there has been little progress in the treatment of
lymphedema beyond prevention through removal of
fewer lymph nodes in fewer women.
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Vulvar cancer is an excellent target for the SLN concept because
the tumor is easy to inject with blue dye and radiocolloid and because
lymph drainage is predictably to one or both of the groins. Multiple
single-institution series6-10 established the feasibility of SLNB in
women with vulvar cancer. The Gynecologic Oncology Group (GOG)
has studied various surgical and radiotherapy techniques for women
with vulvar cancer. Two previous attempts by the GOG to replace full
inguinal femoral lymphadenectomy with either a less radical surgical
procedure or radiotherapy were unsuccessful.11,12 Here, we report the
results of the GOG-173 protocol [Phase III Study of Intraoperative
Lymphatic Mapping in Patients With Invasive Squamous Cell Carci-
noma of the Vulva], a prospective multi-institution validation trial to
determine whether SLNB could replace inguinal femoral lymphade-
nectomy and become the standard for future treatment studies in
women with vulvar cancer.
PATIENTS AND METHODS
Patients
The protocol was open to women at the 47 GOG member institutions
and their affiliates. The institutional review board at each member institution
(Appendix, online only) approved the protocol. Women with invasive squa-
mous cell carcinoma of the vulva were eligible if the depth of invasion was at
least 1 mm, the tumor was limited to the vulva, the primary tumor size was at
least 2 cm and not larger than 6 cm, and there was no suggestion of inguinal
lymph node metastases on physical examination. Women with a previous
wide local excision were eligible if the medical record documented the size of
the primary tumor. The women had to have adequate performance status to
undergo surgery. All women gave written informed consent. Women who had
prior groin irradiation, prior groin dissection, multifocal disease, recurrent
vulvar cancer, or grossly inflamed tumor were excluded.
Protocol and Procedures
There was no requirement for surgeon skill verification since vulvar
cancer is so infrequent in any individual gynecologic oncologist’s practice.
There is no validated number for skill verification in vulvar cancer. At the time
the study was written, the commonly referenced number of patients for a
breast surgeon was 10 to 20. This was impractical for gynecologic oncologists.
Women underwent a complete history and physical examination. A drawing
of the primary tumor was obtained along with demographic and tumor infor-
mation at enrollment. No preoperative cross-sectional imaging was required.
All women underwent intraoperative lymphatic mapping and SLNB
with isosulfan blue dye. At the outset of the study, preoperative lympho-
scintigraphy and intraoperative radiolocalization were optional. Begin-
ning 2 years after study activation, preoperative lymphoscintigraphy and
intraoperative radiolocalization were required (see the Amendments sec-
tion for more information).
The decision to perform unilateral or bilateral SLNB and lymphadenec-
tomy was determined by the location of the primary tumor. If the tumor came
within 2 cm of the midline, bilateral SLNB and lymphadenectomies were
performed regardless of lymphoscintigraphy findings.
Intraoperative intradermal injection of blue dye was performed follow-
ing induction of anesthesia and sterile preparation and draping. Five minutes
after dye injection, an incision was made in the groin, and blue efferent
channels and blue lymph nodes were identified. A lymph node was considered
sentinel if a blue channel led to it, even if the node was not blue. If radiocolloid
was used intraoperatively, a handheld gamma counter was passed over the
nodal tissue to identify lymph nodes emitting the tracer. A radioactive lymph
node was considered sentinel if the activity was at least 10 times greater than
background radioactivity. SLNs were labeled as blue, radioactive (hot), or both
blue and hot. Following SLN identification, a completion lymphadenectomy
was performed for all patients as described in the GOG surgical manual.
Histopathology
The method of labeling and processing SLNs was specified in the proto-
col. SLNs were subjected to ultra staging by serially sectioning them into 3-mm
blocks. Frozen section evaluation was discouraged. At least two sections 40
microns apart were taken from each block and examined to determine
whether they contained tumor cells. If routine hematoxylin and eosin staining
was negative for metastatic disease on the first slide, immunohistochemical
cytokeratin staining was performed on the second slide. Slides of the primary
tumor, including slides demonstrating depth of invasion, were confirmed on
GOG central pathology review; however, slides of lymph node metastases were
not sent for central pathology review.
Statistical Analysis
The primary objective of this study was to estimate the negative
predictive value of a sentinel groin lymph node (ie, the probability of all
unilateral groin lymph nodes from a dissection being negative when the
unilateral sentinel node is negative). By definition, the sentinel diagnostic
procedure is 100% specific and, therefore, the predictive value of the
procedure is a function of two variables: sensitivity (ie, the probability of
the SLN being determined as positive for a patient with at least one positive
groin lymph node from all nodes removed) and the frequency of occult
positive groin nodes. Thus, the statistical design of this study was based on
formulating a lower confidence boundary for the sensitivity (90% confi-
dence or   .10). We assumed that the sensitivity of the procedure would
be constant over the entire population being studied.
A three-phase sampling scheme was designed in the hope of reducing the
required sample size. The decision to stop or continue was based on the
conditional lower confidence boundary (LCB) estimate and its relationship to
the minimally effective sensitivity values of 0.82 and 0.88 for stage I and stage II
disease, respectively. Appendix Table A1 (online only) and Appendix Figure
A1 (online only) give conditional LCBs for various scenarios and stopping
rules, respectively, for the three-phase sampling scheme design. In particular,
the study would close if the sensitivity was less than 0.82 (the minimally
effective level for stage I disease) or if the conditional 90% LCB was greater than
0.88 (the minimally effective level for stage II disease). At the third and final
accrual phase, the decision to consider the procedure effective was based on
observing 104 or more true-positive nodes to detect sensitivity of at least 90%
and false-negative predictive value of no more than 5% with at least 89%
(N = 515) Excluded by centralized GOG 
   modality reviews
(n = 56)
Without any lymph node 
   metastases
With lymph node metastases
Failure to identify any sentinel 
   node
Either LN sampling or SLN 








Fig 1. CONSORT diagram. GOG, Gynecologic Oncology Group; LN, lymph
node; SLN, sentinel lymph node.
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power. A total of 120 lymph node–positive women would be needed to
determine the statistical end points if the study continued through all three
phases. Expected accrual was 20 lymph node–positive women per year in light
of accrual to previous GOG studies. Therefore, it was anticipated that the study
would take a minimum of 2 years and a maximum of 6 years to complete.
Amendments
At the outset, the protocol did not require lymphoscintigraphy, in part
out of concern that the addition of this imaging study would inhibit accrual
because of the cost. Two years after study activation, mounting published
evidence indicated that SLN detection was improved by the addition of pre-
operative lymphoscintigraphy and intraoperative radiolocalization. There-
fore, preoperative lymphoscintigraphy and intraoperative radiolocalization
were made mandatory. In 2007, when a nationwide shortage of isosulfan blue




From December 1999 through January 2009, 515 women were
accrued from 47 member institutions. After disqualifications shown
in the CONSORT diagram (Fig 1), 459 women were eligible and 452
underwent lymphatic mapping, SLNB, and inguinal femoral lymph-
adenectomy. Clinical characteristics of eligible women are provided in
Table 1. In all, 772 groin dissections were performed (bilateral in 320
women and unilateral in 132 women). Table 2 provides details on 418
women who had at least one SLN identified and thus were evaluable
for the sensitivity analysis. No significant allergic reactions to blue dye
were reported.
Incidence of Lymph Node Metastases in Women With
SLNs Identified
The incidence of lymph node metastases among women with at
least one SLN identified was 31.6% (132 of 418). The incidence of
lymph node metastases was significantly higher in women with larger
tumors. Specifically, the rate of lymph node metastases was 26.4% (71
of 269) in women with primary tumors 2.0 to 3.9 cm and 40.9% (61 of
149) in women with primary tumors 4.0 to 6.0 cm (P  .0029). An
analysis of the reliability of the SLN procedure relative to the primary
tumor location is the subject of a secondary pending analysis.
Characteristics of SLNs
Among the 418 women (92.5%) who had at least one SLN iden-
tified at surgery, the SLNs were both blue and hot in 254 women
Table 1. Patient Characteristics (N  459)
Characteristic No. of Patients %
Age, years




























Clinical characteristics of all 459 patients who remained in the study after
centralized Gynecologic Oncology Group (GOG) review, including seven
patients who did not undergo either lymphatic mapping or sentinel lymph
node biopsy.






Present Absent Sensitivity 90% CI NPV (%) 90% CI FNPV (%) 90% CI
By patients Positive 121 0 121
Negative 11 286 297
Total 132 286 418 91.7 86.7 to 95.3 96.3 93.9 to 97.9 3.7 2.1 to 6.1
By groin Positive 140 0 140
Negative 12 441 453
Total 152 441 593 92.1 87.5 to 95.4 97.4 95.7 to 98.5 2.7 1.5 to 4.3
In tumors  4.0 cm Positive 67 0 67
Negative 4 198 202
Total 71 198 269 2.0 0.7 to 4.5
In tumors  4.0 cm Positive 54 0 54
Negative 7 88 95
Total 61 88 149 7.4 3.5 to 13.4
Abbreviations: FNPV, false-negative predictive value; NPV, negative predictive value; SLNB, sentinel lymph node biopsy.
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(61%), were blue only in 100 women (24%), and were hot only in 64
women (15%). The mean number of SLNs per groin was 1.54. The
mean number of all lymph nodes per groin was 8.94 (range, one to 32
lymph nodes; interquartile range, six to 11 lymph nodes).
Rates of SLN identification were similar in the 48 women who had a
prior wide local excision and had blue dye with or without radiocolloid
injected around the scar (87.5%; 42 of 48) and the 376 women who had
blue dye with or without radiocolloid injected around the tumor (93.1%;
376 of 404; P .15). Twenty-one women had SLNs that appeared grossly
involved with tumor at surgery. Of note, the SLN was the only positive
node in 73 (55.3%) of the 132 node-positive women.
Sensitivity Analysis
The sensitivity analysis is summarized in Table 2. Of the 132
node-positive women, 11 had false-negative findings on SLNB (8.3%;
90% CI, 4.7% to 13.4%). The sensitivity was 91.7%, and the false-
negative predictive value [1-negative predictive value] was 3.7%.
When the data were analyzed by groin rather than by patient, the
false-negative predictive value was 2.7%. For women with tumors
smaller than 4 cm, the false-negative predictive value was 2.0%, and
for women with tumors 4 to 6 cm, the false-negative predictive value
was 7.4%.
False-Negative Nodes
The false-negative rates for SLNs identified by dye and radiocol-
loid, dye alone, and radiocolloid alone were 1.6%, 2.0%, and 7.8%,
respectively. Of the 11 false-negative patients, six were the first, second,
or third accession from an institution. Only one institution had two
false-negative patients. Appendix Table A2 (online only) provides a
detailed listing of tumor characteristics, surgery type, and the SLN
identification method for the 11 patients with false-negative results.
Table 3 lists the cumulative number of false-negatives after each ac-
crual phase.
Histopathology
Immunohistochemical analysis of SLNs was performed in 200
(71%) of the 285 women with negative SLNs on routine hematoxylin
and eosin analysis. Twenty-three percent of true-positive cases were
detected by immunohistochemistry when routine hemotoxylin and
eosin staining did not reveal metastatic disease.
DISCUSSION
The study reported here was the latest effort by the GOG to improve
outcomes for women with vulvar cancer. The 1976 GOG-37 protocol
report demonstrated the superiority of groin and pelvic radiotherapy
compared with pelvic lymphadenectomy in women undergoing rad-
ical vulvectomy who had groin metastases.13,14 The GOG has collected
extensive surgical pathologic data confirming the relationship of
depth of invasion to risk of nodal metastases, most notably the insig-
nificant risk of lymph node spread for any depth of invasion less than
1 mm.15 In 1979, DiSaia et al16 proposed that the superficial inguinal
lymph nodes served as SLNs and that if these nodes were negative,
deeper femoral nodes were also negative. They confirmed their obser-
vation in a larger single-institution trial.17 The GOG 74 protocol
[Carcinoma of the Vulva Treated with Ipsilateral Superficial Inguinal
Lymphadenectomy and Modified Radical Hemivulvectomy] was de-
signed to test the utility of superficial inguinal lymphadenectomy in
the group setting; however, the results were disappointing. There was
an unexpectedly high number of groin relapses, and this approach was
abandoned.12 The GOG conducted protocol 88 [RT vs bilateral groin
dissection] to compare lymphadenectomy with groin irradiation;
again, results were disappointing, with an unexpectedly high rate of
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Fig 2. Projected versus actual accrual and incidence of lymph node metastasis.
LN, lymph node; LSG, lymphoscintigraphy.














Positive 127 0 127
Negative 8 268 276
Total 135 268 403 94.1 97.1 2.9
Abbreviations: FNPV, false-negative predictive value; GROINS V, Gronigen
International Sentinel Nodes Vulva study; NPV, negative predictive value;
SLNB, sentinel lymph node biopsy.
Table 3. Cumulative Counts of Eligible Patients, Incidence of Lymph Node
Metastasis, and False Negatives by Accrual Phase (step)
Variable
Accrual Phase
One Two Three Final
Sentinel lymph node
identified
112 273 390 418
Lymph node metastasis 40 80 120 132
False negatives 3 6 10 11
Accrual extended beyond the planned sample size to ensure at least 120
lymph node–positive patients.
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www.jco.org © 2012 by American Society of Clinical Oncology 3789
The results of this trial closely replicate the results of the GROINS
V (Gronigen International Sentinel Nodes Vulva) study.18 This multi-
institutional trial conducted primarily in the Netherlands, used an
observational study design and included women with vulvar cancer
who had primary tumor size less than 4 cm and who had negative
findings on SLNB. Assuming that the eight women with groin relapse
of the 403 women enrolled onto the study represented women with
false-negative findings on SLNB, the false-negative rate in that study
was 5.9%, and the false-negative predictive value was 2.9% (Table 4).
These values are remarkably similar to our false-negative rate and
false-negative predictive value for women with tumors less than 4 cm.
There are several weaknesses of our study that require mention.
First, the study took longer to complete than anticipated. The false-
negative rate might have been lower if surgeon skill verification had
been required. We anticipate that a learning curve would result in a
decreasing rate of false-negative nodes as investigators learned the
procedure. Performance did not improve during the study, presum-
ably because new centers and surgeons were constantly being added.
The amendment to require lymphoscintigraphy coincided with a de-
cline in accrual (Fig 2), suggesting how sensitive GOG member insti-
tutions are to cost. In addition, some individual investigators might
have adopted the procedure as their standard and stopped offering the
study to women since women in the study would require full lymph-
adenectomy. Second, the rate of performance of immunohistochem-
ical analysis was much lower than required by the protocol. There
was some resistance to conducting the costly and time-consuming
immunohistochemistry studies, which suggests poor communication
among gynecologic oncologists, pathologists, and the GOG statistical
office. Since immunohistochemistry detects more true-positive nodes
and reduces the number of false-negative nodes, omission of immu-
nohistochemical analysis might have lengthened the study and led to
an overestimation of the false-negative predictive value. Central re-
view of immunohistochemistry slides was not required, which limits
our analysis regarding the role of the size of the metastases on out-
comes. Third, we were unable to evaluate the impact of the procedure
on groin recurrence risk or on quality of life (because of reduced
surgical evaluation) since all women underwent full lymphadenec-
tomy following the sentinel node procedure. Both outcomes are the
subject of ongoing investigation. Finally, we did not capture compli-
cations that may be unique to the procedure as well as we had planned
to. As experience has grown with mapping studies in other solid
tumors, procedure-specific complications such as hypersensitivity re-
actions, pseudohypoxia, paresthesias, seroma, and infection have been
attributed to the procedure. These effects and their impact on survi-
vorship are important parameters.
On the basis of our experience, we believe that the safety of future
studies that include SLNB will be enhanced if confirmation of institu-
tional competence with the procedure, including pathologic ultra
staging, is obtained. Preoperative imaging provides an opportunity to
exclude women with grossly involved but not palpable SLNs who
might benefit by going directly to lymphadenectomy. Finally, future
studies should define single grossly involved lymph nodes that are not
hot or blue as sentinel, since they are clearly the first site of metastases.
In conclusion, this study met its predetermined statistical goals
for the incorporation of SLNB into future GOG treatment studies of
women with vulvar cancer. Women with primary tumors smaller
than 4 cm who met the eligibility criteria for this trial can be counseled
preoperatively that if the SLN is negative, they have a less than 3% risk
of a groin relapse due to a false-negative SLN. With the addition of
preparative imaging, growing surgical experience, and improved his-
topathologic techniques, it is hoped that this rate can be reduced even
further. We believe that the results of this trial coupled with the results
of the GROINS V study provide adequate evidence that SLNB should
be offered to well-selected patients by well-trained and informed gy-
necologic oncologists. In clinical settings where vulvar cancer is rare
and surgeons’ experience is limited, referral to a high-volume center or
surgeon is appropriate.
The management of women with positive findings on SLNB was
not addressed in this study. There is extensive literature from other
disease sites that indicate the size of the metastasis is a critical element
in determining treatment. There may even be false-positive patients in
whom the identification of micrometastases or isolated tumor cells is
clinically insignificant. Categorizing immunohistochemistry-only pa-
tients as node positive can lead to overtreatment. Nevertheless, treat-
ment guidelines from breast cancer should not be adapted to vulvar
cancer without further investigation in spite of parallels in the devel-
opment of surgery for both diseases. Squamous cell carcinoma of the
vulva is not hormonally active or chemosensitive. Patients with vulvar
cancer who relapse frequently do so locally and die from locally ad-
vanced disease. This is in contrast to many breast cancers that are
considered sensitive to chemotherapy and hormonal therapy.
The GOG (GOG 270 study) has joined the Gronigen Interna-
tional Study on Sentinel Nodes in Vulvar Cancer (GROINSS VII),
which addresses the management of SLN-positive women. The pro-
tocol requires surgeon skill verification, preoperative imaging, and
central pathology review. We hope that international collaboration
will help shorten the duration of studies that improve outcomes for
women with vulvar cancer.
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